Literature DB >> 30348014

Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project.

Matilda Bäckberg1, Madeleine Pettersson Bergstrand2,3, Olof Beck2,4, Anders Helander2,3,4.   

Abstract

CONTEXT: In recent years, many unclassified benzodiazepines (BZD) have appeared through online sale as new psychoactive substances (NPS). This study describes bioanalytical and clinical data related to intoxications involving NPS BZD ("designer BZD") in the Swedish STRIDA project. STUDY
DESIGN: Case series of consecutive patients with admitted or suspected intake of NPS presenting to hospitals all over Sweden for emergency treatment in 2012-2016. PATIENTS AND
METHOD: Urine samples collected in the STRIDA project were analyzed for 28 NPS BZD, using immunoassay and liquid chromatography-high-resolution mass spectrometry . Data of patient's age, gender, reported substance exposure, clinical signs, and treatment were obtained from medical and Poisons Information Center (PIC) records.
RESULTS: A total of fifteen different NPS BZD were analytically confirmed in 217 of 1913 (11%) cases involving patients (81% men) aged 15-66 (mean 28) years. The frequency of positive samples increased from 4% in 2012 to 19% in 2015. Etizolam (20 cases) was the first detected NPS BZD (January 2012), and it was followed by metizolam (four cases), estazolam (two), pyrazolam (33), flubromazepam (33), nifoxipam (five), diclazepam (four), meclonazepam (26), bromazepam (one), flubromazolam (92), deschloroetizolam (one), clonazolam (16), 3-hydroxyphenazepam (eight), ketazolam (one), and phenazepam (one). Most cases (89%) also involved other drugs. Use of NPS BZD was rarely (15%) reported during PIC consultation. In 24 patients exposed only to NPS BZD, CNS depression was the most prominent clinical sign, seven were observed in the intensive care unit, and they responded positively to flumazenil treatment.
CONCLUSIONS: An increasing use of NPS BZD in Sweden was detected in acute intoxication cases, sometimes leading to intensive care monitoring and support needs.

Entities:  

Keywords:  Designer benzodiazepines; intoxications; liquid chromatography–mass spectrometry; new psychoactive substances

Mesh:

Substances:

Year:  2018        PMID: 30348014     DOI: 10.1080/15563650.2018.1506130

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  7 in total

1.  The designer benzodiazepine, flubromazepam, induces reward-enhancing and cardiotoxic effects in rodents.

Authors:  Eunchong Hong; Sun Mi Gu; Jin Mook Kim; Kyung Sik Yoon; Jin-Moo Lee; Young-Hoon Kim; Soo Kyung Suh; Dohyun Lee; Heejong Eom; Jaesuk Yun; Hye Jin Cha
Journal:  Toxicol Res (Camb)       Date:  2022-07-08       Impact factor: 2.680

2.  A New Strategy for Efficient Retrospective Data Analyses for Designer Benzodiazepines in Large LC-HRMS Datasets.

Authors:  Meiru Pan; Brian Schou Rasmussen; Petur Weihe Dalsgaard; Christian Brinch Mollerup; Marie Katrine Klose Nielsen; Michael Nedahl; Kristian Linnet; Marie Mardal
Journal:  Front Chem       Date:  2022-05-19       Impact factor: 5.545

3.  Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project.

Authors:  Anders Helander; Matilda Bäckberg; Olof Beck
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

Review 4.  'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.

Authors:  Laura Orsolini; John M Corkery; Stefania Chiappini; Amira Guirguis; Alessandro Vento; Domenico De Berardis; Duccio Papanti; Fabrizio Schifano
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 5.  Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.

Authors:  Pietro Brunetti; Raffaele Giorgetti; Adriano Tagliabracci; Marilyn A Huestis; Francesco Paolo Busardò
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11

Review 6.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

7.  Pearl powder reduces sleep disturbance stress response through regulating proteomics in a rat model of sleep deprivation.

Authors:  Meng Xia; Delun Huang; Yuangming Tong; Jiang Lin
Journal:  J Cell Mol Med       Date:  2020-03-27       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.